TCT-841 Baseline characteristics and 3-month outcomes of the EVOLVE Short DAPT Trial: A prospective investigation of abbreviated antiplatelet therapy in high bleeding risk patients treated with a thin-strut bioabsorbable polymer-coated, everolimus-eluting coronary stent

Autor:	Stephan Windecker, Harold L. Dauerman, Bernardo Stein, Naeem Tahirkheli, Robert W. Yeh, Matthew J. Price, Dominic Allocco, Ralph Toelg, Robert C. Stoler, Laura Mauri, Dean J. Kereiakes, Franz-Josef Neumann, Robert L. Feldman, Ajay J. Kirtane, Loukas Boutis, Islam Othman, Paul Underwood, Ian Meredith
Rok vydání:	2018
Předmět:	medicine.medical_specialty Everolimus business.industry medicine.medical_treatment technology industry and agriculture Stent equipment and supplies Bioabsorbable polymer Surgery Baseline characteristics Coronary stent medicine Drug release Cardiology and Cardiovascular Medicine business medicine.drug
Zdroj:	Journal of the American College of Cardiology. 72:B335-B336
ISSN:	0735-1097
DOI:	10.1016/j.jacc.2018.08.2086
Popis:	The SYNERGY stent (Boston Scientific) is a thin-strut platinum chromium metal alloy platform eluting everolimus from an ultrathin abluminal layer of poly(DL-lactide-co-glycolide) bioabsorbable polymer. Drug release and polymer degradation are complete within 4 months of implantation. These design
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::4a237b60354d6198ded0e6f45dcecde2 https://doi.org/10.1016/j.jacc.2018.08.2086 Zobrazit plný text záznamu